investorscraft@gmail.com

Stock Analysis & ValuationNeuphoria Therapeutics Inc. (NEUP)

Previous Close
$5.22
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)11.28116
Graham-Dodd Method7.9652
Graham Formulan/a

Company Information

100 Summit Dr
Burlington
United States
Industry: Medical - Pharmaceuticals
Sector: Healthcare
CEO: Spyridon Papapetropoulos
Full Time Employees: 8

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

HomeMenuAccount